article thumbnail

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

During the American Society of Clinical Oncology (ASCO) 2023 annual meeting, BioNTech revealed promising Phase I results for the pancreatic cancer drug BNT122 combined with the immune checkpoint inhibitor (ICI) atezolizumab. percent of the total mRNA therapy market by 2029. percent of the total mRNA therapy market by 2029.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BioNTech to lead $2 bn mRNA-based oncology therapy market despite challenges: GlobalData

Express Pharma

The trial, conducted in collaboration with Memorial Sloan Kettering Cancer Center and in partnership with Genentech, combines BNT122 with the immune checkpoint inhibitor (ICI) atezolizumab. OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2

article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

GlobalData stated that if development is successful for Ultragenyx’s OTX-2002 , which has potential to be the first programmable epigenetic medicine, it could generate $1.6 billion during 2028. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

article thumbnail

Sore Throat

RX Note

Indications for Referral Sore throat duration >2 weeks or hoarseness of longer than 3 weeks' duration Suggests nonacute cause and require further investigation Difficulty in swallowing ( dysphagia ) Suggests sinister pathology Patents taking medications that can interfere with the immune response (e.g.

article thumbnail

Changing Faces: biopharma hires from November 2022

pharmaphorum

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. Diaz has been with Almirall since 2002, most recently serving as senior director of corporate strategy.

article thumbnail

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

PharmaShots

Company: Jazz Pharmaceuticals Generic Name: Sodium Oxybate First Approval Date: Jul 17, 2002 Patent Expiration: Jun 2023 2022 Sales: $1B Indication: Narcolepsy Xyrem is an oral solution for treating two common symptoms of narcolepsy, i.e., excessive daytime sleepiness (EDS) and cataplexy.